Skip to main content
NCBI home page
Virologica Sinica logoLink to Virologica Sinica
. 2014 Dec 15;29(6):327–342. doi: 10.1007/s12250-014-3539-2

Ocular herpes: the pathophysiology, management and treatment of herpetic eye diseases

Lucy Zhu 1, Hua Zhu 1,✉
PMCID: PMC8206444  PMID: 25547680

Abstract

Herpesviruses are a prominent cause of human viral disease, second only to the cold and influenza viruses. Most herpesvirus infections are mild or asymptomatic. However, when the virus invades the eye, a number of pathologies can develop and its associated sequelae have become a considerable source of ocular morbidity. The most common culprits of herpetic eye disease are the herpes simplex virus (HSV), varicella zoster virus (VZV), and cytomegalovirus (CMV). While primary infection can produce ocular disease, the most destructive manifestations tend to arise from recurrent infection. These recurrent infections can wreck devastating effects and lead to irreversible vision loss accompanied by a decreased quality of life, increased healthcare usage, and significant cost burden. Unfortunately, no method currently exists to eradicate herpesviruses from the body after infection. Treatment and management of herpes-related eye conditions continue to revolve around antiviral drugs, although corticosteroids, interferons, and other newer therapies may also be appropriate depending on the disease presentation. Ultimately, the advent of effective vaccines will be crucial to preventing herpesvirus diseases altogether and cutting the incidence of ocular complications.

Keywords: ocular herpes, herpetic eye diseases, varicella zoster virus (VZV), cytomegalovirus (CMV), herpes simplex virus (HSV)

Footnotes

This article is published with open access at Springerlink.com

References

  1. Akhtar J, Shukla D. Viral entry mechanisms: cellular and viral mediators of herpes simplex virus entry. FEBS J. 2009;276:7228–7236. doi: 10.1111/j.1742-4658.2009.07402.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Al-Dujaili L J, Clerkin P P, Clement C, McFerrin H E, Bhattacharjee P S, Varnell E D, Kaufman H E, Hill J M. Ocular herpes simplex virus: how are latency, reactivation, recurrent disease and therapy interrelated? Future Microbiol. 2011;6:877–907. doi: 10.2217/fmb.11.73. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Anderson J R, Behrens C, Binswanger I A. posting date. HIV Web Study. 2013. [Google Scholar]
  4. Arvin A M. Varicella-zoster virus. Clin Microbiol Rev. 1996;9:361–381. doi: 10.1128/cmr.9.3.361. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Arvin A M. Human herpesviruses: biology, therapy, and immunoprophylaxis. Cambridge; New York: Cambridge University Press; 2007. pp. 1262–1273. [PubMed] [Google Scholar]
  6. Azwa A, Barton S E. Aspects of herpes simplex virus: a clinical review. J Fam Plann Reprod Health Care. 2009;35:237–242. doi: 10.1783/147118909789587376. [DOI] [PubMed] [Google Scholar]
  7. Barron B A, Gee L, Hauck W W, Kurinij N, Dawson C R, Jones D B, Wilhelmus K R, Kaufman H E, Sugar J, Hyndiuk R A, Laibson P R, Stulting R D, Asbell P A. Herpetic Eye Disease Study. A controlled trial of oral acyclovir for herpes simplex stromal keratitis. Ophthalmology. 1994;101:1871–1882. doi: 10.1016/s0161-6420(13)31155-5. [DOI] [PubMed] [Google Scholar]
  8. Belshe R B, Leone P A, Bernstein D I, Wald A, Levin M J, Stapleton J T, Gorfinkel I, Morrow R L, Ewell M G, Stokes-Riner A, Dubin G, Heineman T C, Schulte J M, Deal C D, Herpevac Trial for Women Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med. 2012;366:34–43. doi: 10.1056/NEJMoa1103151. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Bloom J N, Palestine A G. The diagnosis of cytomegalovirus retinitis. Ann Intern Med. 1988;109:963–969. doi: 10.7326/0003-4819-109-12-963. [DOI] [PubMed] [Google Scholar]
  10. Bowen E F, Griffiths P D, Davey C C, Emery V C, Johnson M A. Lessons from the natural history of cytomegalovirus. AIDS. 1996;10(Suppl1):S37–S41. [PubMed] [Google Scholar]
  11. Bradley H, Markowitz L E, Gibson T, McQuillan G M. Seroprevalence of herpes simplex virus types 1 and 2—United States, 1999–2010. J Infect Dis. 2014;209:325–333. doi: 10.1093/infdis/jit458. [DOI] [PubMed] [Google Scholar]
  12. Buxbaum S, Geers M, Gross G, Schofer H, Rabenau H F, Doerr H W. Epidemiology of herpes simplex virus types 1 and 2 in Germany: what has changed? Med Microbiol Immunol. 2003;192:177–181. doi: 10.1007/s00430-003-0183-0. [DOI] [PubMed] [Google Scholar]
  13. Caserta M T, Mock D J, Dewhurst S. Human herpesvirus 6. Clin Infect Dis. 2001;33:829–833. doi: 10.1086/322691. [DOI] [PubMed] [Google Scholar]
  14. Cobo L M, Foulks G N, Liesegang T, Lass J, Sutphin J E, Wilhelmus K, Jones D B, Chapman S, Segreti A C, King D H. Oral acyclovir in the treatment of acute herpes zoster ophthalmicus. Ophthalmology. 1986;93:763–770. doi: 10.1016/s0161-6420(86)33678-9. [DOI] [PubMed] [Google Scholar]
  15. Coleman J L, Shukla D. Recent advances in vaccine development for herpes simplex virus types I and II. Hum Vaccin Immunother. 2013;9:729–735. doi: 10.4161/hv.23289. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Colin J, Chastel C, Kaufman H E, Kissling G E. Combination therapy for dendritic keratitis with acyclovir and vidarabine. J Ocul Pharmacol. 1987;3:39–42. doi: 10.1089/jop.1987.3.39. [DOI] [PubMed] [Google Scholar]
  17. Daibata M, Komatsu T, Taguchi H. Human herpesviruses in primary ocular lymphoma. Leuk Lymphoma. 2000;37:361–365. doi: 10.3109/10428190009089436. [DOI] [PubMed] [Google Scholar]
  18. Damato E G, Winnen C W. Cytomegalovirus infection: perinatal implications. J Obstet Gynecol Neonatal Nurs. 2002;31:86–92. doi: 10.1111/j.1552-6909.2002.tb00026.x. [DOI] [PubMed] [Google Scholar]
  19. Darougar S, Wishart M S, Viswalingam N D. Epidemiological and clinical features of primary herpes simplex virus ocular infection. Br J Ophthalmol. 1985;69:2–6. doi: 10.1136/bjo.69.1.2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Dartt D A, Dana R, D’Amore p, Niederkorn J. Immunology, Inflammation and Diseases of the Eye. San Diego: Academic Press; 2011. [Google Scholar]
  21. Farhatullah S, Kaza S, Athmanathan S, Garg P, Reddy S B, Sharma S. Diagnosis of herpes simplex virus-1 keratitis using Giemsa stain, immunofluorescence assay, and polymerase chain reaction assay on corneal scrapings. Br J Ophthalmol. 2004;88:142–144. doi: 10.1136/bjo.88.1.142. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Farooq A V, Shukla D. Herpes simplex epithelial and stromal keratitis: an epidemiologic update. Surv Ophthalmol. 2012;57:448–462. doi: 10.1016/j.survophthal.2012.01.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Farooq A V, Shah A, Shukla D. The role of herpesviruses in ocular infections. Virus Adaptation and Treatment. 2010;2:115–123. [Google Scholar]
  24. Fulop T, Larbi A, Pawelec G. Human T cell aging and the impact of persistent viral infections. Front Immunol. 2013;4:271. doi: 10.3389/fimmu.2013.00271. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Gershon A A, Gershon M D. Perspectives on vaccines against varicella-zoster virus infections. Curr Top Microbiol Immunol. 2010;342:359–372. doi: 10.1007/82_2010_12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Gilden D H, Dueland A N, Devlin M E, Mahalingam R, Cohrs R. Varicella-zoster virus reactivation without rash. J Infect Dis. 1992;166Suppl1:S30–S34. doi: 10.1093/infdis/166.supplement_1.s30. [DOI] [PubMed] [Google Scholar]
  27. Gimenez F, Suryawanshi A, Rouse B T. Pathogenesis of herpes stromal keratitis—a focus on corneal neovascularization. Prog Retin Eye Res. 2013;33:1–9. doi: 10.1016/j.preteyeres.2012.07.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Green L K, Pavan-Langston D. Herpes simplex ocular inflammatory disease. Int Ophthalmol Clin. 2006;46:27–37. doi: 10.1097/00004397-200604620-00005. [DOI] [PubMed] [Google Scholar]
  29. Gross G, Schofer H, Wassilew S, Friese K, Timm A, Guthoff R, Pau H W, Malin J P, Wutzler P, Doerr H W. Herpes zoster guideline of the German Dermatology Society (DDG) J Clin Virol. 2003;26:277–289. doi: 10.1016/s1386-6532(03)00005-2. [DOI] [PubMed] [Google Scholar]
  30. Guess S, Stone D U, Chodosh J. Evidence-based treatment of herpes simplex virus keratitis: a systematic review. Ocul Surf. 2007;5:240–250. doi: 10.1016/s1542-0124(12)70614-6. [DOI] [PubMed] [Google Scholar]
  31. Hamrah P, Sahin A, Dastjerdi M H, Shahatit B M, Bayhan H A, Dana R, Pavan-Langston D. Cellular changes of the corneal epithelium and stroma in herpes simplex keratitis: an in vivo confocal microscopy study. Ophthalmology. 2012;119:1791–1797. doi: 10.1016/j.ophtha.2012.03.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Hennis H L, Scott A A, Apple D J. Cytomegalovirus retinitis. Surv Ophthalmol. 1989;34:193–203. doi: 10.1016/0039-6257(89)90103-3. [DOI] [PubMed] [Google Scholar]
  33. Hori J. Mechanisms of immune privilege in the anterior segment of the eye: what we learn from corneal transplantation. J Ocul Biol Dis Infor. 2008;1:94–100. doi: 10.1007/s12177-008-9010-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Hung S O, Patterson A, Rees P J. Pharmacokinetics of oral acyclovir (Zovirax) in the eye. Br J Ophthalmol. 1984;68:192–195. doi: 10.1136/bjo.68.3.192. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Hwang C W, Jr., Steigleman W A, Saucedo-Sanchez E, Tuli S S. Reactivation of herpes zoster keratitis in an adult after varicella zoster vaccination. Cornea. 2013;32:508–509. doi: 10.1097/ICO.0b013e318277acae. [DOI] [PubMed] [Google Scholar]
  36. Kahloun R, Attia S, Jelliti B, Attia A Z, Khochtali S, Yahia S B, Zaouali S, Khairallah M. Ocular involvement and visual outcome of herpes zoster ophthalmicus: review of 45 patients from Tunisia, North Africa. J Ophthalmic Inflamm Infect. 2014;4:25. doi: 10.1186/s12348-014-0025-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Karsten E, Watson S L, Foster L J. Diversity of microbial species implicated in keratitis: a review. Open Ophthalmol J. 2012;6:110–124. doi: 10.2174/1874364101206010110. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Kaufman H E. Clinical cure of herpes simplex keratitis by 5-iodo-2-deoxyuridine. Proc Soc Exp Biol Med. 1962;109:251–252. doi: 10.3181/00379727-109-27169. [DOI] [PubMed] [Google Scholar]
  39. Keating G M. Shingles (herpes zoster) vaccine (zostavax(®)): a review of its use in the prevention of herpes zoster and postherpetic neuralgia in adults aged ≥50 years. Drugs. 2013;73:1227–1244. doi: 10.1007/s40265-013-0088-1. [DOI] [PubMed] [Google Scholar]
  40. Kim S R, Khan F, Ramirez-Fort M K, Downing C, Tyring S K. Varicella zoster: an update on current treatment options and future perspectives. Expert Opin Pharmacother. 2014;15:61–71. doi: 10.1517/14656566.2014.860443. [DOI] [PubMed] [Google Scholar]
  41. Knickelbein J E, Hendricks R L, Charukamnoetkanok P. Management of herpes simplex virus stromal keratitis: an evidence-based review. Surv Ophthalmol. 2009;54:226–234. doi: 10.1016/j.survophthal.2008.12.004. [DOI] [PubMed] [Google Scholar]
  42. Kwong A D, Frenkel N. Herpes simplex virus-infected cells contain a function(s) that destabilizes both host and viral mRNAs. Proc Natl Acad Sci USA. 1987;84:1926–1930. doi: 10.1073/pnas.84.7.1926. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Labetoulle M, Auquier P, Conrad H, Crochard A, Daniloski M, Bouee S, El Hasnaoui A, Colin J. Incidence of herpes simplex virus keratitis in France. Ophthalmology. 2005;112:888–895. doi: 10.1016/j.ophtha.2004.11.052. [DOI] [PubMed] [Google Scholar]
  44. Lairson D R, Begley C E, Reynolds T F, Wilhelmus K R. Prevention of herpes simplex virus eye disease: a cost-effectiveness analysis. Arch Ophthalmol. 2003;121:108–112. doi: 10.1001/archopht.121.1.108. [DOI] [PubMed] [Google Scholar]
  45. Liesegang T J. Biology and molecular aspects of herpes simplex and varicella-zoster virus infections. Ophthalmology. 1992;99:781–799. doi: 10.1016/s0161-6420(92)31921-9. [DOI] [PubMed] [Google Scholar]
  46. Liesegang T J. Herpes zoster ophthalmicus natural history, risk factors, clinical presentation, and morbidity. Ophthalmology. 2008;115:S3–S12. doi: 10.1016/j.ophtha.2007.10.009. [DOI] [PubMed] [Google Scholar]
  47. Liesegang T J, Melton L J, 3rd, Daly P J, Ilstrup D M. Epidemiology of ocular herpes simplex. Incidence in Rochester, Minn, 1950 through 1982. Arch Ophthalmol. 1989;107:1155–1159. doi: 10.1001/archopht.1989.01070020221029. [DOI] [PubMed] [Google Scholar]
  48. Liu S, Pavan-Langston D, Colby K A. Pediatric herpes simplex of the anterior segment: characteristics, treatment, and outcomes. Ophthalmology. 2012;119:2003–2008. doi: 10.1016/j.ophtha.2012.05.008. [DOI] [PubMed] [Google Scholar]
  49. Matoba A Y. Ocular disease associated with Epstein-Barr virus infection. Surv Ophthalmol. 1990;35:145–150. doi: 10.1016/0039-6257(90)90069-8. [DOI] [PubMed] [Google Scholar]
  50. Matsuo T, Itami M. Seropositivity of human herpesvirus-8 in patients with uveitis. Ocul Immunol Inflamm. 2002;10:197–199. doi: 10.1076/ocii.10.3.197.15602. [DOI] [PubMed] [Google Scholar]
  51. Mechai F, Boutolleau D, Manceron V, Gasnault J, Quertainmont Y, Brosseau J P, Delfraissy J F, Labetoulle M, Goujard C. Human herpesvirus 6-associated retrobulbar optic neuritis in an HIV-infected patient: response to anti-herpesvirus therapy and long-term outcome. J Med Virol. 2007;79:931–934. doi: 10.1002/jmv.20833. [DOI] [PubMed] [Google Scholar]
  52. Murray P R, Rosenthal K S, Pfaller M A. Human Herpesviruses Medical microbiology. 5th ed. Philadelphia: Elsevier Mosby; 2005. pp. 461–484. [Google Scholar]
  53. Musch D C, Martin D F, Gordon J F, Davis M D, Kuppermann B D. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. The Ganciclovir Implant Study Group. N Engl J Med. 1997;337:83–90. doi: 10.1056/NEJM199707103370203. [DOI] [PubMed] [Google Scholar]
  54. Newman H, Gooding C. Viral ocular manifestations: a broad overview. Rev Med Virol. 2013;23:281–294. doi: 10.1002/rmv.1749. [DOI] [PubMed] [Google Scholar]
  55. Nguyen L H, Knipe D M, Finberg R W. Replication-defective mutants of herpes simplex virus (HSV) induce cellular immunity and protect against lethal HSV infection. J Virol. 1992;66:7067–7072. doi: 10.1128/jvi.66.12.7067-7072.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Nguyen Q D, Kempen J H, Bolton S G, Dunn J P, Jabs D A. Immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis after highly active antiretroviral therapy. Am J Ophthalmol. 2000;129:634–639. doi: 10.1016/s0002-9394(00)00356-1. [DOI] [PubMed] [Google Scholar]
  57. Nilsen A, Myrmel H. Changing trends in genital herpes simplex virus infection in Bergen, Norway. Acta Obstet Gynecol Scand. 2000;79:693–696. [PubMed] [Google Scholar]
  58. Ogata N, Koike N, Yoshikawa T, Takahashi K. Human herpesvirus 6-associated uveitis with optic neuritis diagnosed by multiplex PCR. Jpn J Ophthalmol. 2011;55:502–505. doi: 10.1007/s10384-011-0069-4. [DOI] [PubMed] [Google Scholar]
  59. Ohara P T, Chin M S, LaVail J H. The spread of herpes simplex virus type 1 from trigeminal neurons to the murine cornea: an immunoelectron microscopy study. J Virol. 2000;74:4776–4786. doi: 10.1128/jvi.74.10.4776-4786.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Opstelten W, Zaal M J. Managing ophthalmic herpes zoster in primary care. BMJ. 2005;331:147–151. doi: 10.1136/bmj.331.7509.147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Oxman M N, Levin M J, Johnson G R, Schmader K E, Straus S E, Gelb L D, Arbeit R D, Simberkoff M S, Gershon A A, Davis L E, Weinberg A, Boardman K D, Williams H M, Zhang J H, Peduzzi P N, Beisel C E, Morrison V A, Guatelli J C, Brooks P A, Kauffman C A, Pachucki C T, Neuzil K M, Betts R F, Wright P F, Griffin M R, Brunell P, Soto N E, Marques A R, Keay S K, Goodman R P, Cotton D J, Gnann J W, Jr., Loutit J, Holodniy M, Keitel W A, Crawford G E, Yeh S S, Lobo Z, Toney J F, Greenberg R N, Keller P M, Harbecke R, Hayward A R, Irwin M R, Kyriakides T C, Chan C Y, Chan I S, Wang W W, Annunziato P W, Silber J L, Shingles Prevention Study G A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352:2271–2284. doi: 10.1056/NEJMoa051016. [DOI] [PubMed] [Google Scholar]
  62. Palestine A G. Clinical aspects of cytomegalovirus retinitis. Rev Infect Dis. 1988;10(Suppl3):S515–S521. doi: 10.1093/clinids/10.supplement_3.s515. [DOI] [PubMed] [Google Scholar]
  63. Papaloukas O, Giannouli G, Papaevangelou V. Successes and challenges in varicella vaccine. Ther Adv Vaccines. 2014;2:39–55. doi: 10.1177/2051013613515621. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Pepose J S, Keadle T L, Morrison L A. Ocular herpes simplex: changing epidemiology, emerging disease patterns, and the potential of vaccine prevention and therapy. Am J Ophthalmol. 2006;141:547–557. doi: 10.1016/j.ajo.2005.10.008. [DOI] [PubMed] [Google Scholar]
  65. Centers for Disease Control and Prevention. 2012. Epidemiology and Prevention of Vaccine-Preventable Diseases. Atkinson W, Wolfe S, Hamborsky J, eds. 12th ed., second printing. Washington DC: Public Health Foundation, pp301–324.
  66. Prober C G, Kirk L E, Keeney R E. Acyclovir therapy of chickenpox in immunosuppressed children—a collaborative study. J Pediatr. 1982;101:622–625. doi: 10.1016/s0022-3476(82)80725-7. [DOI] [PubMed] [Google Scholar]
  67. Rabenau H F, Buxbaum S, Preiser W, Weber B, Doerr H W. Seroprevalence of herpes simplex virus types 1 and type 2 in the Frankfurt am Main area, Germany. Med Microbiol Immunol. 2002;190:153–160. doi: 10.1007/s00430-001-0102-1. [DOI] [PubMed] [Google Scholar]
  68. Revere K, Davidson S L. Update on management of herpes keratitis in children. Curr Opin Ophthalmol. 2013;24:343–347. doi: 10.1097/ICU.0b013e32836227d8. [DOI] [PubMed] [Google Scholar]
  69. Rocha G, Muzychuk M. Herpes Zoster Ophthalmicus: More than meets the eye. Clinical & Surgical Ophthalmology. 2010;28:11–16. [Google Scholar]
  70. Rowe A M, St Leger A J, Jeon S, Dhaliwal D K, Knickelbein J E, Hendricks R L. Herpes keratitis. Prog Retin Eye Res. 2013;32:88–101. doi: 10.1016/j.preteyeres.2012.08.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. Roy F H, Fraunfelder F W, Fraunfelder F T. Roy and Fraunfelder’s Current Ocular Therapy. 2008. [Google Scholar]
  72. Sacchetti M, Lambiase A. Diagnosis and management of neurotrophic keratitis. Clin Ophthalmol. 2014;8:571–579. doi: 10.2147/OPTH.S45921. [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Schmader K, Gnann J W, Jr., Watson C P. The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. J Infect Dis. 2008;197(Suppl2):S207–S215. doi: 10.1086/522152. [DOI] [PubMed] [Google Scholar]
  74. Schreiber A, Harter G, Schubert A, Bunjes D, Mertens T, Michel D. Antiviral treatment of cytomegalovirus infection and resistant strains. Expert Opin Pharmacother. 2009;10:191–209. doi: 10.1517/14656560802678138. [DOI] [PubMed] [Google Scholar]
  75. Scoular A, Norrie J, Gillespie G, Mir N, Carman W F. Longitudinal study of genital infection by herpes simplex virus type 1 in Western Scotland over 15 years. BMJ. 2002;324:1366–1367. doi: 10.1136/bmj.324.7350.1366. [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. Shaikh S, Ta C N. Evaluation and management of herpes zoster ophthalmicus. Am Fam Physician. 2002;66:1723–1730. [PubMed] [Google Scholar]
  77. Simberkoff M S, Arbeit R D, Johnson G R, Oxman M N, Boardman K D, Williams H M, Levin M J, Schmader K E, Gelb L D, Keay S, Neuzil K, Greenberg R N, Griffin M R, Davis L E, Morrison V A, Annunziato P W, Shingles Prevention Study G. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Ann Intern Med. 2010;152:545–554. doi: 10.7326/0003-4819-152-9-201005040-00004. [DOI] [PubMed] [Google Scholar]
  78. Slobod K S, Sandlund J T, Spiegel P H, Haik B, Hurwitz J L, Conley M E, Bowman L C, Benaim E, Jenkins J J, Stocks R M, Gan Y, Sixbey J W. Molecular evidence of ocular Epstein-Barr virus infection. Clin Infect Dis. 2000;31:184–188. doi: 10.1086/313932. [DOI] [PubMed] [Google Scholar]
  79. Smith J S, Robinson N J. Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. J Infect Dis. 2002;186(Suppl1):S3–S28. doi: 10.1086/343739. [DOI] [PubMed] [Google Scholar]
  80. Stanberry L R, Spruance S L, Cunningham A L, Bernstein D I, Mindel A, Sacks S, Tyring S, Aoki F Y, Slaoui M, Denis M, Vandepapeliere P, Dubin G, GlaxoSmithKline Herpes Vaccine Efficacy Study G. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med. 2002;347:1652–1661. doi: 10.1056/NEJMoa011915. [DOI] [PubMed] [Google Scholar]
  81. Stein-Streilein J. Immune regulation and the eye. Trends Immunol. 2008;29:548–554. doi: 10.1016/j.it.2008.08.002. [DOI] [PubMed] [Google Scholar]
  82. Steiner I, Kennedy P G, Pachner A R. The neurotropic herpes viruses: herpes simplex and varicella-zoster. Lancet Neurol. 2007;6:1015–1028. doi: 10.1016/S1474-4422(07)70267-3. [DOI] [PubMed] [Google Scholar]
  83. Stewart M W. Optimal management of cytomegalovirus retinitis in patients with AIDS. Clin Ophthalmol. 2010;4:285–299. doi: 10.2147/opth.s6700. [DOI] [PMC free article] [PubMed] [Google Scholar]
  84. Sundmacher R. Color atlas of herpetic eye disease: a practical guide to clinical management. Berlin: Springer; 2009. pp. 51–56. [Google Scholar]
  85. Sung H, Schleiss M R. Update on the current status of cytomegalovirus vaccines. Expert Rev Vaccines. 2010;9:1303–1314. doi: 10.1586/erv.10.125. [DOI] [PMC free article] [PubMed] [Google Scholar]
  86. Suzuki T, Ohashi Y. Corneal endotheliitis. Semin Ophthalmol. 2008;23:235–240. doi: 10.1080/08820530802111010. [DOI] [PubMed] [Google Scholar]
  87. Tappuni A R. Immune reconstitution inflammatory syndrome. Adv Dent Res. 2011;23:90–96. doi: 10.1177/0022034511399915. [DOI] [PubMed] [Google Scholar]
  88. Tasman W, Jaeger E A. Duane’s ophthalmology on DVD-ROM-2013 edition. 2013. [Google Scholar]
  89. Toma H S, Murina A T, Areaux R G, Jr., Neumann D M, Bhattacharjee P S, Foster T P, Kaufman H E, Hill J M. Ocular HSV-1 latency, reactivation and recurrent disease. Semin Ophthalmol. 2008;23:249–273. doi: 10.1080/08820530802111085. [DOI] [PubMed] [Google Scholar]
  90. Tran T, Druce J D, Catton M C, Kelly H, Birch C J. Changing epidemiology of genital herpes simplex virus infection in Melbourne, Australia, between 1980 and 2003. Sex Transm Infect. 2004;80:277–279. doi: 10.1136/sti.2004.009753. [DOI] [PMC free article] [PubMed] [Google Scholar]
  91. Tyring S K. Mucosal immunology and virology. London: Springer; 2006. pp. 179–189. [Google Scholar]
  92. Tyring S K. Management of herpes zoster and postherpetic neuralgia. J Am Acad Dermatol. 2007;57:S136–S142. doi: 10.1016/j.jaad.2007.09.016. [DOI] [PubMed] [Google Scholar]
  93. Varani S, Landini M P. Cytomegalovirus-induced immunopathology and its clinical consequences. Herpesviridae. 2011;2:6. doi: 10.1186/2042-4280-2-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  94. Varani S, Spezzacatena P, Manfredi R, Chiodo F, Mastroianni A, Ballarini P, Boschini A, Lazzarotto T, Landini M P. The incidence of cytomegalovirus (CMV) antigenemia and CMV disease is reduced by highly active antiretroviral therapy. Eur J Epidemiol. 2000;16:433–437. doi: 10.1023/a:1007619323939. [DOI] [PubMed] [Google Scholar]
  95. Weinberg A, Zhang J H, Oxman M N, Johnson G R, Hayward A R, Caulfield M J, Irwin M R, Clair J, Smith J G, Stanley H, Marchese R D, Harbecke R, Williams H M, Chan I S, Arbeit R D, Gershon A A, Schodel F, Morrison V A, Kauffman C A, Straus S E, Schmader K E, Davis L E, Levin M J, US Department of Veterans Affairs VA Cooperative Studies Program Shingles Prevention Study Investigators Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis. 2009;200:1068–1077. doi: 10.1086/605611. [DOI] [PMC free article] [PubMed] [Google Scholar]
  96. Wenkel H, Rummelt V, Fleckenstein B, Naumann G O. Detection of varicella zoster virus DNA and viral antigen in human eyes after herpes zoster ophthalmicus. Ophthalmology. 1998;105:1323–1330. doi: 10.1016/S0161-6420(98)97042-7. [DOI] [PubMed] [Google Scholar]
  97. Whitcup S M. Cytomegalovirus retinitis in the era of highly active antiretroviral therapy. JAMA. 2000;283:653–657. doi: 10.1001/jama.283.5.653. [DOI] [PubMed] [Google Scholar]
  98. Wilhelmus K R. Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis. Cochrane Database Syst Rev. 2010;12:CD002898. doi: 10.1002/14651858.CD002898.pub4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  99. Wilhelmus K R, Falcon M G, Jones B R. Bilateral herpetic keratitis. Br J Ophthalmol. 1981;65:385–387. doi: 10.1136/bjo.65.6.385. [DOI] [PMC free article] [PubMed] [Google Scholar]
  100. Wong R W, Jumper J M, McDonald H R, Johnson R N, Fu A, Lujan B J, Cunningham E T., Jr. Emerging concepts in the management of acute retinal necrosis. Br J Ophthalmol. 2013;97:545–552. doi: 10.1136/bjophthalmol-2012-301983. [DOI] [PubMed] [Google Scholar]
  101. Xu F, Sternberg M R, Kottiri B J, McQuillan G M, Lee F K, Nahmias A J, Berman S M, Markowitz L E. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA. 2006;296:964–973. doi: 10.1001/jama.296.8.964. [DOI] [PubMed] [Google Scholar]
  102. Yawn B P, Wollan P C, St Sauver J L, Butterfield L C. Herpes zoster eye complications: rates and trends. Mayo Clin Proc. 2013;88:562–570. doi: 10.1016/j.mayocp.2013.03.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  103. Yen M, Ausayakhun S, Chen J, Ausayakhun S, Jirawison C, Heiden D, Holland G N, Margolis T P, Keenan J D. Telemedicine diagnosis of cytomegalovirus retinitis by nonophthalmologists. JAMA Ophthalmol. 2014;132:1052–1058. doi: 10.1001/jamaophthalmol.2014.1108. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Virologica Sinica are provided here courtesy of Wuhan Institute of Virology, Chinese Academy of Sciences

RESOURCES